EE03002B1 - 1,3-oksatiolaannukleosiidi analoogid, neid sisaldavad ravimpreparaadid ja nende valmistamise meetod - Google Patents

1,3-oksatiolaannukleosiidi analoogid, neid sisaldavad ravimpreparaadid ja nende valmistamise meetod

Info

Publication number
EE03002B1
EE03002B1 EE9400261A EE9400261A EE03002B1 EE 03002 B1 EE03002 B1 EE 03002B1 EE 9400261 A EE9400261 A EE 9400261A EE 9400261 A EE9400261 A EE 9400261A EE 03002 B1 EE03002 B1 EE 03002B1
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical preparations
preparations containing
nucleoside analogues
oxathiolane nucleoside
Prior art date
Application number
EE9400261A
Other languages
English (en)
Inventor
Dionne Gervais
Original Assignee
Biochem Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biochem Pharma Inc. filed Critical Biochem Pharma Inc.
Publication of EE03002B1 publication Critical patent/EE03002B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
EE9400261A 1991-08-01 1994-10-20 1,3-oksatiolaannukleosiidi analoogid, neid sisaldavad ravimpreparaadid ja nende valmistamise meetod EE03002B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues

Publications (1)

Publication Number Publication Date
EE03002B1 true EE03002B1 (et) 1997-06-16

Family

ID=10699340

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400261A EE03002B1 (et) 1991-08-01 1994-10-20 1,3-oksatiolaannukleosiidi analoogid, neid sisaldavad ravimpreparaadid ja nende valmistamise meetod

Country Status (41)

Country Link
US (2) US5538975A (et)
EP (2) EP1155695B1 (et)
JP (1) JP2960778B2 (et)
KR (1) KR100242454B1 (et)
CN (5) CN1034810C (et)
AP (1) AP321A (et)
AT (2) ATE448787T1 (et)
AU (1) AU659668B2 (et)
BG (1) BG61693B1 (et)
CA (2) CA2114221C (et)
CZ (1) CZ283765B6 (et)
DE (2) DE69232845T2 (et)
DK (2) DK0526253T3 (et)
EE (1) EE03002B1 (et)
EG (1) EG20193A (et)
ES (2) ES2335968T3 (et)
FI (1) FI940435A0 (et)
GB (1) GB9116601D0 (et)
GE (1) GEP20002094B (et)
HK (2) HK1008672A1 (et)
HN (1) HN1997000118A (et)
HU (2) HUT70030A (et)
IL (1) IL102616A (et)
MA (1) MA22919A1 (et)
MD (1) MD1434C2 (et)
MX (1) MX9204474A (et)
NO (3) NO300842B1 (et)
NZ (1) NZ243637A (et)
OA (1) OA09883A (et)
PH (1) PH30983A (et)
PT (2) PT526253E (et)
RS (1) RS49993B (et)
RU (1) RU2126405C1 (et)
SG (1) SG68541A1 (et)
SK (1) SK280131B6 (et)
TJ (1) TJ244R3 (et)
TN (1) TNSN92070A1 (et)
TW (2) TW366347B (et)
WO (1) WO1993003027A1 (et)
YU (1) YU49259B (et)
ZA (1) ZA925668B (et)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6071922A (en) 1997-03-19 2000-06-06 Emory University Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
RU2439069C2 (ru) 1998-08-12 2012-01-10 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиолановых нуклеозидов
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ATE287268T1 (de) 1998-11-02 2005-02-15 Gilead Sciences Inc Kombinationstherapie zur behandlung von hepatitis b infektionen
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
ATE339211T1 (de) 2000-03-29 2006-10-15 Univ Georgetown L-fmau zur behandlung von hepatitis-delta-virus- infizierung
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
CA2690137C (en) * 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
WO2003051298A2 (en) * 2001-12-14 2003-06-26 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CN102482639B (zh) 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2012365627B2 (en) 2012-01-10 2017-05-25 C.C.Jensen A/S Method and system for cleaning degraded oil
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
DE69233693T2 (de) * 1991-03-06 2008-01-24 Emory University Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
IL102616A0 (en) 1993-01-14
CZ20394A3 (en) 1994-07-13
NO300842B1 (no) 1997-08-04
SK10494A3 (en) 1994-12-07
PH30983A (en) 1997-12-23
NO940322D0 (no) 1994-01-31
IL102616A (en) 1996-10-31
AU659668B2 (en) 1995-05-25
CA2682254C (en) 2012-02-21
ES2186667T3 (es) 2003-05-16
US5538975A (en) 1996-07-23
YU74992A (sh) 1995-12-04
TNSN92070A1 (fr) 1993-06-08
YU72303A (sh) 2006-05-25
DK1155695T3 (da) 2010-04-06
DK0526253T3 (da) 2003-03-17
FI940435A (fi) 1994-01-28
GB9116601D0 (en) 1991-09-18
DE69232845D1 (de) 2002-12-19
NO2008009I1 (no) 2008-06-30
MD1434B2 (en) 2000-03-31
DE69233776D1 (de) 2009-12-31
OA09883A (en) 1994-09-15
KR100242454B1 (ko) 2000-03-02
JP2960778B2 (ja) 1999-10-12
AP9200414A0 (en) 1992-07-31
CN1070191A (zh) 1993-03-24
CN1074924C (zh) 2001-11-21
PT526253E (pt) 2003-03-31
CA2114221A1 (en) 1993-02-18
BG61693B1 (bg) 1998-03-31
CZ283765B6 (cs) 1998-06-17
AU2340892A (en) 1993-03-02
CN101066970A (zh) 2007-11-07
EP1155695B1 (en) 2009-11-18
ES2335968T3 (es) 2010-04-07
NO940322L (no) 1994-03-21
TWI232217B (en) 2005-05-11
CA2114221C (en) 2009-12-22
CN1302612A (zh) 2001-07-11
CA2682254A1 (en) 1993-02-18
MX9204474A (es) 1993-12-01
SK280131B6 (sk) 1999-08-06
ATE448787T1 (de) 2009-12-15
GEP20002094B (en) 2000-05-10
DE69232845T2 (de) 2003-04-24
HK1008672A1 (en) 1999-05-14
CN1132073A (zh) 1996-10-02
EG20193A (en) 1997-10-30
ATE227720T1 (de) 2002-11-15
MA22919A1 (fr) 1993-04-01
CN101074228A (zh) 2007-11-21
US5618820A (en) 1997-04-08
TW366347B (en) 1999-08-11
NO2005017I1 (no) 2005-09-05
NZ243637A (en) 1995-03-28
TJ244R3 (en) 1999-11-24
PT1155695E (pt) 2010-02-02
HK1038189A1 (en) 2002-03-08
EP1155695A1 (en) 2001-11-21
RS49993B (sr) 2008-09-29
SG68541A1 (en) 1999-11-16
ZA925668B (en) 1993-04-28
HU9400285D0 (en) 1994-05-30
FI940435A0 (fi) 1994-01-28
HN1997000118A (es) 1999-11-12
MD950114A (en) 1996-06-28
MD1434C2 (ro) 2000-12-31
EP0526253A1 (en) 1993-02-03
YU49259B (sh) 2004-12-31
JPH07500317A (ja) 1995-01-12
WO1993003027A1 (en) 1993-02-18
EP0526253B1 (en) 2002-11-13
RU2126405C1 (ru) 1999-02-20
HU211333A9 (en) 1995-11-28
BG98616A (bg) 1995-03-31
CN1034810C (zh) 1997-05-07
CN100542535C (zh) 2009-09-23
AP321A (en) 1994-02-28
NO2005017I2 (no) 2007-10-01
HUT70030A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
EE03002B1 (et) 1,3-oksatiolaannukleosiidi analoogid, neid sisaldavad ravimpreparaadid ja nende valmistamise meetod
EE9400455A (et) Peptiidi derivaadid, nende valmistamise protsess, neid sisaldavad ravimpreparaadid ja nende kasutamine
FI942181A0 (fi) Uudet lupaanijohdannaiset, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
IL98025A0 (en) 1,3-oxathiolane nucleoside analogues,methods for the preparation thereof and pharmaceutical compositions containing the same
EE03110B1 (et) Steroidi estrid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
EE9400428A (et) Isatiini derivaadid, nende valmistamise protsess, neid sisaldavad ravimvormid ja nende kasutamine
IL91126A0 (en) Substituted aminomethyl-tetralins and their heterocyclic analogues,their preparation and pharmaceutical compositions containing them
IL91129A0 (en) Aminomethyloxooxazolidinyl arylbenzene derivatives,their preparation and pharmaceutical compositions containing them
IL90245A0 (en) Ethenediamine derivatives,their preparation and pharmaceutical compositions containing them
EE03111B1 (et) Glükokortikosteroidi epimeerid, nende valmistamise protsessid ja neid sisaldavad ravimpreparaadid
DE3480599D1 (de) 1-hydroxypyrid-2-on-derivate enthaltende pharmazeutische zubereitungen.
IT1232149B (it) Composizione farmaceutica contenente ranitidina, e metodo per prepararla
FI94591B (fi) Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi
EE9400326A (et) Opioidpeptiidi analoogid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
EE9400070A (et) Bioloogiliselt aktiivsed eburnameniini derivaadid, neid sisaldavad farmatseutilised segud ja nende valmistamise protsess
IL92710A0 (en) 2-iminobenzothiazoline derivatives,their preparation and pharmaceutical compositions containing them
IL89084A0 (en) Benzodioxole derivatives,their preparation and pharmaceutical compositions containing them
KR900012897A (ko) 구아니딘 유도체 및 이를 함유하는 약제학적 조성물
IL91245A0 (en) Benzopyranol derivatives,their preparation and pharmaceutical compositions containing them
EE9400148A (et) Tienotiasiini derivaadid, nende valmistamise meetod ja neid sisaldavad farmatseutilised preparaadid
IL92634A0 (en) Adenosine derivatives,their preparation and pharmaceutical compositions containing them
NZ221350A (en) Uridine derivatives and pharmaceutical preparation
IL90002A0 (en) Phosphonoalkylpurine derivatives,their preparation and pharmaceutical compositions containing them
IL85738A0 (en) Nucleoside derivatives,their preparation and pharmaceutical compositions containing them
IL90567A0 (en) Nucleoside derivatives,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

AA1Y Spc filed

Free format text: PRODUCT NAME: TRUVADA; REG NO/DATE: EU/1/04/305/001 21.02.2005

Spc suppl protection certif: C20050004

Filing date: 20050809

Free format text: PRODUCT NAME: EMTRIVA; REG NO/DATE: EU/1/03/261/001 24.10.2003 EU/1/03/261/002 24.10.2003 EU/1/03/261/003 24.10.2003

Spc suppl protection certif: C20050005

Filing date: 20050809

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

FC1Y Spc application refused

Free format text: PRODUCT NAME: EMTRIVA; REG NO/DATE: EU/1/03/261/001 24.10.2003 EU/1/03/261/002 24.10.2003 EU/1/03/261/003 24.10.2003

Spc suppl protection certif: C20050005

Filing date: 20050809

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

AA1Y Spc filed

Free format text: PRODUCT NAME: ATRIPLA; REG NO/DATE: EU/1/07/430/001 13.12.2007

Spc suppl protection certif: C20080002

Filing date: 20080612

FG1Y Spc granted

Free format text: PRODUCT NAME: ATRIPLA; REG NO/DATE: EU/1/07/430/001 13.12.2007

Spc suppl protection certif: C20080002 00017

Filing date: 20080612

Extension date: 20191020

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCX Term of validity of supplementary protection expired

Spc suppl protection certif: 00017

Extension date: 20160525

MC1Y Annulment of an spc

Spc suppl protection certif: 00010